Company registration number 08292124 (England and Wales)
SSP HEALTH HOLDING LTD
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED
30 MARCH 2025
30 March 2025
SSP HEALTH HOLDING LTD
COMPANY INFORMATION
Director
Dr S Pitalia
Company number
08292124
Registered office
3rd Floor Waterside House
Waterside Drive
Wigan
WN3 5AZ
Auditor
AMS Audit Limited
1 Hardman Street
Spinningfields
Manchester
M3 3HF
SSP HEALTH HOLDING LTD
CONTENTS
Page
Strategic report
1 - 2
Director's report
3 - 4
Independent auditor's report
5 - 7
Group statement of comprehensive income
8
Group balance sheet
9
Company balance sheet
10
Group statement of changes in equity
11
Company statement of changes in equity
12
Group statement of cash flows
13
Notes to the financial statements
14 - 32
SSP HEALTH HOLDING LTD
STRATEGIC REPORT
FOR THE YEAR ENDED 30 MARCH 2025
- 1 -
The director presents the strategic report for the year ended 30 March 2025.
Review of the business
The group is an established provider of NHS services throughout the North West of England with a reputation for delivering a first class service.
The group has invested in the growth and infrastructure of the business during the year in order to support future performance and the directors are satisfied with the results of the group.
Group turnover for the year was £16,905,536 (2024: £12,529,136) with a profit before tax of £2,605,389 (2024: £628,455).
Principal risks and uncertainties
One of the principal risks affecting the group in prior years was the expiration of the APMS contracts and the contracts not being renewed. All contracts due for recent renewal have been renewed without issue and all of our surgeries maintain a “Good” or “Outstanding” rating, we believe any future risk here to be low and continue to monitor.
The group uses various financial instruments including cash, trade debtors and trade creditors that arise directly from its operations. The main purpose of this is to finance the group’s operations.
The main risks arising from the group’s financial instruments are market risk, liquidity risk, interest rate risk and credit risk. The directors review and agree policies for managing each of these risks and they are summarised below:-
Market Risk
Market risk encompasses three types of risk being currency risk, fair value interest rate risk and price risk. The group’s policies for managing fair value interest rate risk are considered along with those for managing cash flow interest rate risk and are set out in the subsection entitled “Interest Rate Risk” below. The group is not currently exposed to price risk or currency risk.
Liquidity Risk
The group seeks to manage financial risk by ensuring sufficient liquidity is available to meet foreseeable needs to invest cash assets safely and profitably. Short term flexibility is achieved by overdraft facilities however they are rarely used.
Interest rate risk
The group finances its operations through retained profits and therefore the directors do not consider this to be a risk to the group.
Credit risk
The group's principal financial assets are cash and trade debtors. The credit risk associated with the cash is limited, and the principal credit risk arises therefore from its trade debtors. It's main customer is the NHS, therefore this risk is considered minimal due to them paying promptly after the invoice has been raised.
Key performance indicators
The main financial metrics used by the Director in assessing business performance is turnover, net profit, EBITDA and cash flow. These KPI's are monitored on a monthly basis to ensure the group continues to drive forward and generate healthy profits and cashflow.
SSP HEALTH HOLDING LTD
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
- 2 -
Dr S Pitalia
Director
17 November 2025
SSP HEALTH HOLDING LTD
DIRECTOR'S REPORT
FOR THE YEAR ENDED 30 MARCH 2025
- 3 -
The director presents her annual report and financial statements for the year ended 30 March 2025.
Principal activities
The principal activity of the company and group continued to be that of the provision of medical services.
Results and dividends
The results for the year are set out on page 8.
Ordinary dividends were paid amounting to £3,250,000. The director does not recommend payment of a further dividend.
Director
The director who held office during the year and up to the date of signature of the financial statements was as follows:
Dr S Pitalia
Disabled persons
Applications for employment by disabled persons are always fully considered, bearing in mind the aptitudes of the applicant concerned. In the event of members of staff becoming disabled, every effort is made to ensure that their employment within the group continues and that the appropriate training is arranged. It is the policy of the group that the training, career development and promotion of disabled persons should, as far as possible, be identical to that of other employees.
Employee involvement
The group's policy is to consult and discuss with employees, through unions, staff councils and at meetings, matters likely to affect employees' interests.
Information about matters of concern to employees is given through information bulletins and reports which seek to achieve a common awareness on the part of all employees of the financial and economic factors affecting the group's performance.
Auditor
The auditor, AMS Audit Limited, is deemed to be reappointed under section 487(2) of the Companies Act 2006.
Statement of director's responsibilities
The director is responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.
United Kingdom company law requires the director to prepare financial statements for each financial year. Under that law, the director has elected to prepare the group and parent company financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the director must not approve the financial statements unless she is satisfied that they give a true and fair view of the state of affairs of the group and parent company, and of the profit or loss of the group for that period.
In preparing these financial statements, the director is required to:
select suitable accounting policies and then apply them consistently;
make judgements and accounting estimates that are reasonable and prudent;
state whether applicable United Kingdom Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the group and parent company will continue in business.
SSP HEALTH HOLDING LTD
DIRECTOR'S REPORT (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
- 4 -
The director is responsible for keeping adequate accounting records that are sufficient to show and explain the group’s and parent company’s transactions and disclose with reasonable accuracy at any time the financial position of the group and parent company, and enable them to ensure that the financial statements comply with the Companies Act 2006. She is also responsible for safeguarding the assets of the group and parent company, and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Strategic report
Ttruehe group has chosen in accordance with Companies Act 2006, s. 414C(11) to set out in the group's strategic report information required by Large and Medium-sized Companies and Groups (Accounts and Reports) Regulations 2008, Sch. 7 to be contained in the directors' report. It has done so in respect of its financial risk management objectives and policies.
Statement of disclosure to auditor
So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the auditor of the company is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the auditor of the company is aware of that information.
Medium-sized companies exemption
This report has been prepared in accordance with the provisions applicable to groups and companies entitled to the exemptions of the small companies regime.
On behalf of the board
Dr S Pitalia
Director
17 November 2025
SSP HEALTH HOLDING LTD
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF SSP HEALTH HOLDING LTD
- 5 -
Opinion
We have audited the financial statements of SSP Health Holding Ltd (the 'parent company') and its subsidiaries (the 'group') for the year ended 30 March 2025 which comprise the group statement of comprehensive income, the group balance sheet, the company balance sheet, the group statement of changes in equity, the company statement of changes in equity, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).
In our opinion the financial statements:
give a true and fair view of the state of the group's and the parent company's affairs as at 30 March 2025 and of the group's profit for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the director's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the director with respect to going concern are described in the relevant sections of this report.
The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The director is responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of our audit:
The information given in the strategic report and the director's report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
The strategic report and the director's report have been prepared in accordance with applicable legal requirements.
SSP HEALTH HOLDING LTD
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF SSP HEALTH HOLDING LTD
- 6 -
Matters on which we are required to report by exception
In the light of the knowledge and understanding of the group and the parent company and their environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the director's report.
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:
adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or
the parent company financial statements are not in agreement with the accounting records and returns; or
certain disclosures of directors' remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit.
Responsibilities of director
As explained more fully in the director's responsibilities statement, the director is responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the director determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the director is responsible for assessing the group's and parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the director either intends to liquidate the group or parent company or to cease operations, or has no realistic alternative but to do so.
Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.
We gained an understanding of the legal and regulatory framework applicable to the Group and the industry in which it operates, drawing on our broad sector experience, and considered the risk of acts by the Group that were contrary to these laws and regulations, including fraud. We focused on laws and regulations that could give rise to a material misstatement in the financial statements, including, but not limited to, the Quality Care Commission (CQC), Companies Act 2006 and equivalent local laws and regulations.
We made enquiries of management with regards to compliance with the above laws and regulations and corroborated any necessary evidence to relevant information, for example, minutes of the board meetings, legal reports provided to the company and group and correspondence between the company and group and its solicitors. Audit procedures performed by the engagement team included:
Discussion with management, including consideration of known or suspected instances of noncompliance with laws and regulations and fraud;
Review of financial statement disclosures to underlying supporting documentation;
Challenging assumptions and judgements made by management in their significant accounting estimates;
Our audit procedures were designed to respond to risks of material misstatement in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery, misrepresentations or through collusion. There are inherent limitations in the audit procedures performed and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we are to become aware of it.
SSP HEALTH HOLDING LTD
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF SSP HEALTH HOLDING LTD
- 7 -
A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.
This report is made solely to the parent company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the parent company’s members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the parent company and the parent company’s members as a body, for our audit work, for this report, or for the opinions we have formed.
Andrew Davis ACCA CTA MAAT (Senior Statutory Auditor)
For and on behalf of AMS Audit Limited, Statutory Auditor
Chartered Accountants
1 Hardman Street
Spinningfields
Manchester
M3 3HF
17 November 2025
SSP HEALTH HOLDING LTD
GROUP STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 30 MARCH 2025
- 8 -
2025
2024
as restated
Notes
£
£
Turnover
3
16,905,536
12,529,136
Cost of sales
(153,999)
(199,280)
Gross profit
16,751,537
12,329,856
Administrative expenses
(14,334,484)
(12,214,258)
Other operating income
80,371
430,344
Operating profit
4
2,497,424
545,942
Interest receivable and similar income
6
108,379
82,513
Interest payable and similar expenses
7
(414)
-
Profit before taxation
2,605,389
628,455
Tax on profit
8
(635,893)
(122,930)
Profit for the financial year
23
1,969,496
505,525
Profit for the financial year is all attributable to the owners of the parent company.
Total comprehensive income for the year is all attributable to the owners of the parent company.
The profit and loss account has been prepared on the basis that all operations are continuing operations.
SSP HEALTH HOLDING LTD
GROUP BALANCE SHEET
AS AT
30 MARCH 2025
30 March 2025
- 9 -
2025
2024
as restated
Notes
£
£
£
£
Fixed assets
Intangible assets
10
94,337
107,814
Tangible assets
11
437,127
253,591
Investment property
12
3,627,098
1,354,341
Investments
13
74,237
-
4,232,799
1,715,746
Current assets
Stocks
16
58,070
58,070
Debtors
17
2,254,792
3,124,094
Cash at bank and in hand
3,607,573
2,821,921
5,920,435
6,004,085
Creditors: amounts falling due within one year
18
(7,355,770)
(3,627,387)
Net current (liabilities)/assets
(1,435,335)
2,376,698
Total assets less current liabilities
2,797,464
4,092,444
Provisions for liabilities
Deferred tax liability
20
30,876
45,352
(30,876)
(45,352)
Net assets
2,766,588
4,047,092
Capital and reserves
Called up share capital
22
100
100
Profit and loss reserves
23
2,766,488
4,046,992
Total equity
2,766,588
4,047,092
These financial statements have been prepared in accordance with the provisions relating to medium-sized groups.
The financial statements were approved and signed by the director and authorised for issue on 17 November 2025
17 November 2025
Dr S Pitalia
Director
Company registration number 08292124 (England and Wales)
SSP HEALTH HOLDING LTD
COMPANY BALANCE SHEET
AS AT 30 MARCH 2025
30 March 2025
- 10 -
2025
2024
as restated
Notes
£
£
£
£
Fixed assets
Investments
13
74,438
101
Current assets
Debtors
17
5,244,123
1,421,769
Cash at bank and in hand
2,011,338
584
7,255,461
1,422,353
Creditors: amounts falling due within one year
18
(7,316,645)
(446,010)
Net current (liabilities)/assets
(61,184)
976,343
Net assets
13,254
976,444
Capital and reserves
Called up share capital
22
100
100
Profit and loss reserves
23
13,154
976,344
Total equity
13,254
976,444
As permitted by section 408 of the Companies Act 2006, the company has not presented its own profit and loss account and related notes. The company’s profit for the year was £2,286,810 (2024 - £32,927 loss).
The financial statements were approved and signed by the director and authorised for issue on 17 November 2025
17 November 2025
Dr S Pitalia
Director
Company registration number 08292124 (England and Wales)
SSP HEALTH HOLDING LTD
GROUP STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 MARCH 2025
- 11 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
As restated for the period ended 30 March 2024:
Balance at 31 March 2023
100
8,829,904
8,830,004
Year ended 30 March 2024:
Profit and total comprehensive income
-
505,525
505,525
Dividends
9
-
(5,288,437)
(5,288,437)
Balance at 30 March 2024
100
4,046,992
4,047,092
Year ended 30 March 2025:
Profit and total comprehensive income
-
1,969,496
1,969,496
Dividends
9
-
(3,250,000)
(3,250,000)
Balance at 30 March 2025
100
2,766,488
2,766,588
SSP HEALTH HOLDING LTD
COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 MARCH 2025
- 12 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
As restated for the period ended 30 March 2024:
Balance at 31 March 2023
100
6,297,708
6,297,808
Year ended 30 March 2024:
Loss and total comprehensive income for the year
-
(32,927)
(32,927)
Dividends
9
-
(5,288,437)
(5,288,437)
Balance at 30 March 2024
100
976,344
976,444
Year ended 30 March 2025:
Profit and total comprehensive income
-
2,286,810
2,286,810
Dividends
9
-
(3,250,000)
(3,250,000)
Balance at 30 March 2025
100
13,154
13,254
SSP HEALTH HOLDING LTD
GROUP STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 30 MARCH 2025
- 13 -
2025
2024
as restated
Notes
£
£
£
£
Cash flows from operating activities
Cash generated from operations
26
4,159,812
2,480,180
Interest paid
(414)
-
Income taxes paid
(232,125)
(320,958)
Net cash inflow from operating activities
3,927,273
2,159,222
Investing activities
Purchase of tangible fixed assets
-
(125,998)
Purchase of investment property
-
(629,341)
Interest received
108,379
121,468
Net cash generated from/(used in) investing activities
108,379
(633,871)
Financing activities
Dividends paid to equity shareholders
(3,250,000)
(250,000)
Net cash used in financing activities
(3,250,000)
(250,000)
Net increase in cash and cash equivalents
785,652
1,275,351
Cash and cash equivalents at beginning of year
2,821,921
1,546,570
Cash and cash equivalents at end of year
3,607,573
2,821,921
SSP HEALTH HOLDING LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 MARCH 2025
- 14 -
1
Accounting policies
Company information
SSP Health Holding Ltd (“the company”) is a private limited company domiciled and incorporated in England and Wales. The registered office is 3rd Floor Waterside House, Waterside Drive, Wigan, England, WN3 5AZ.
The group consists of SSP Health Holding Ltd and all of its subsidiaries.
1.1
Basis of preparation
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
The company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements for parent company information presented within the consolidated financial statements:
Section 7 ‘Statement of Cash Flows’: Presentation of a statement of cash flow and related notes and disclosures;false
Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instrument Issuestrue: Interest income/expense and net gains/losses for financial instruments not measured at fair value; basis of determining fair values; details of collateral, loan defaults or breaches, details of hedges, hedging fair value changes recognised in profit or loss and in other comprehensive income;
Section 26 ‘Share based Payment’true: Share-based payment expense charged to profit or loss, reconciliation of opening and closing number and weighted average exercise price of share options, how the fair value of options granted was measured, measurement and carrying amount of liabilities for cash-settled share-based payments, explanation of modifications to arrangements;
Section 33 ‘Related Party Disclosures’true: Compensation for key management personnel.
1.2
Business combinations
In the parent company financial statements, the cost of a business combination is the fair value at the acquisition date of the assets given, equity instruments issued and liabilities incurred or assumed, plus costs directly attributable to the business combination. The excess of the cost of a business combination over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recognised as goodwill. The cost of the combination includes the estimated amount of contingent consideration that is probable and can be measured reliably, and is adjusted for changes in contingent consideration after the acquisition date. Provisional fair values recognised for business combinations in previous periods are adjusted retrospectively for final fair values determined in the 12 months following the acquisition date. Investments in subsidiaries, joint ventures and associates are accounted for at cost less impairment.
Deferred tax is recognised on differences between the value of assets (other than goodwill) and liabilities recognised in a business combination accounted for using the purchase method and the amounts that can be deducted or assessed for tax, considering the manner in which the carrying amount of the asset or liability is expected to be recovered or settled. The deferred tax recognised is adjusted against goodwill or negative goodwill.
SSP HEALTH HOLDING LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
1
Accounting policies
(Continued)
- 15 -
1.3
Basis of consolidation
The consolidated group financial statements consist of the financial statements of the parent company SSP Health Holding Ltd together with all entities controlled by the parent company (its subsidiaries) and the group’s share of its interests in joint ventures and associates.
All financial statements are made up to 30 March 2025. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by other members of the group.
All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.
Group companies listed in note 15 have been included in the group financial statements using the purchase method of accounting. Accordingly, the group profit and loss account and statement of cash flows include the results and cash flows of group companies from the date of acquisition up until the date of disposal. The purchase consideration has been allocated to the assets and liabilities on the basis of fair value at the date of acquisition.
1.4
Going concern
Atruet the time of approving the financial statements, the director had a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the director continues to adopt the going concern basis of accounting in preparing the financial statements.
The company and group continues to have the support of is bankers and its shareholders who will make funds available to meet the liabilities and obligations as they fall due. Therefore, the director deems it appropriate to prepare the financial statements on a going concern basis.
1.5
Revenue
Turnover is recognised at the fair value of the consideration received or receivable for services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.
Medical services income is recognised at the point of delivery.
When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.
1.6
Intangible fixed assets other than goodwill
Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.
Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.
Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Software development costs
10 years
SSP HEALTH HOLDING LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
1
Accounting policies
(Continued)
- 16 -
1.7
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Leasehold land and buildings
2% straight line
Plant and equipment
25% straight line
Fixtures and fittings
15% straight line
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the profit and loss account.
1.8
Investment property
Investment property, which is property held to earn rentals and/or for capital appreciation, is initially recognised at cost, which includes the purchase cost and any directly attributable expenditure. Subsequently it is measured at fair value at the reporting end date. Changes in fair value are recognised in profit or loss.
1.9
Fixed asset investments
Equity investments are measured at fair value through profit or loss, except for those equity investments that are not publicly traded and whose fair value cannot otherwise be measured reliably, which are recognised at cost less impairment until a reliable measure of fair value becomes available.
In the parent company financial statements, investments in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses.
A subsidiary is an entity controlled by the group. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.
An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The group considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.
Investments in associates are initially recognised at the transaction price (including transaction costs) and are subsequently adjusted to reflect the group’s share of the profit or loss, other comprehensive income and equity of the associate using the equity method. Any difference between the cost of acquisition and the share of the fair value of the net identifiable assets of the associate on acquisition is recognised as goodwill. Any unamortised balance of goodwill is included in the carrying value of the investment in associates.
Losses in excess of the carrying amount of an investment in an associate are recorded as a provision only when the company has incurred legal or constructive obligations or has made payments on behalf of the associate.
In the parent company financial statements, investments in associates are accounted for at cost less impairment.
Entities in which the group has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.
SSP HEALTH HOLDING LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
1
Accounting policies
(Continued)
- 17 -
1.10
Impairment of fixed assets
At each reporting period end date, the group reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.
The carrying amount of the investments accounted for using the equity method is tested for impairment as a single asset. Any goodwill included in the carrying amount of the investment is not tested separately for impairment.
Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.
If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.
Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.
1.11
Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.
Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.
1.12
Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
SSP HEALTH HOLDING LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
1
Accounting policies
(Continued)
- 18 -
1.13
Financial instruments
The group has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the group's balance sheet when the group becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
Other financial assets
Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.
Impairment of financial assets
Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.
Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.
If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.
Derecognition of financial assets
Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the group transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the group after deducting all of its liabilities.
SSP HEALTH HOLDING LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
1
Accounting policies
(Continued)
- 19 -
Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
Other financial liabilities
Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.
Debt instruments that do not meet the conditions in FRS 102 paragraph 11.9 are subsequently measured at fair value through profit or loss. Debt instruments may be designated as being measured at fair value through profit or loss to eliminate or reduce an accounting mismatch or if the instruments are measured and their performance evaluated on a fair value basis in accordance with a documented risk management or investment strategy.
Derecognition of financial liabilities
Financial liabilities are derecognised when the group's contractual obligations expire or are discharged or cancelled.
1.14
Equity instruments
Equity instruments issued by the group are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the group.
1.15
Derivatives
Derivatives are initially recognised at fair value at the date a derivative contract is entered into and are subsequently remeasured to fair value at each reporting end date. The resulting gain or loss is recognised in profit or loss immediately unless the derivative is designated and effective as a hedging instrument, in which event the timing of the recognition in profit or loss depends on the nature of the hedge relationship.
A derivative with a positive fair value is recognised as a financial asset, whereas a derivative with a negative fair value is recognised as a financial liability.
1.16
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The group’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
SSP HEALTH HOLDING LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
1
Accounting policies
(Continued)
- 20 -
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset if, and only if, there is a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
1.17
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
1.18
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
1.19
Leases
As lessee
Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leased asset are consumed.
As lessor
When the group acts as a lessor, a lease is classified as a finance lease whenever it transfers substantially all the risks and rewards of ownership of the underlying asset to the lessee, either at the end of the lease term or for the major part of the economic life of the asset. All other leases are classified as operating leases. If an arrangement contains both lease and non-lease components, the group allocates the consideration in the contract to the two elements.
Rental income from operating leases is recognised on a straight line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised on a straight line basis over the lease term.
1.20
Foreign exchange
Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.
SSP HEALTH HOLDING LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
- 21 -
2
Judgements and key sources of estimation uncertainty
In the application of the group’s accounting policies, the director is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
Critical judgements
The following judgements (apart from those involving estimates) have had the most significant effect on amounts recognised in the financial statements.
Fair value of investment property
The company policy is to engage a Chartered Surveyor to carry out a valuation of investment properties held by the company at regular intervals. During the interim periods, the director reviews rent yields in consultation with a review of the local property market to ensure that fair value disclosed in the financial statements remains appropriate.
The director does not consider there are any other critical judgements or sources of estimation uncertainty requiring disclosure.
3
Turnover and other revenue
An analysis of the group's turnover is as follows:
2025
2024
£
£
Turnover analysed by class of business
Medical services
16,905,536
12,529,136
2025
2024
£
£
Other revenue
Interest income
108,379
82,513
4
Operating profit
2025
2024
£
£
Operating profit for the year is stated after charging:
Fees payable to the group's auditor for the audit of the group's financial statements
24,000
20,000
Depreciation of tangible fixed assets
59,645
43,114
Amortisation of intangible assets
13,477
13,477
Operating lease charges
86,129
-
SSP HEALTH HOLDING LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
- 22 -
5
Employees
The average monthly number of persons (including directors) employed by the group and company during the year was:
Group
Company
2025
2024
2025
2024
Number
Number
Number
Number
Management and administration
334
174
1
1
Their aggregate remuneration comprised:
Group
Company
2025
2024
2025
2024
£
£
£
£
Wages and salaries
11,432,469
9,106,763
Social security costs
586,383
384,217
-
-
Pension costs
248,352
266,824
12,267,204
9,757,804
6
Interest receivable and similar income
2025
2024
£
£
Interest income
Interest on bank deposits
71,111
27,505
Other interest income
37,268
55,008
Total income
108,379
82,513
7
Interest payable and similar expenses
2025
2024
£
£
Interest on bank overdrafts and loans
414
-
8
Taxation
2025
2024
£
£
Current tax
UK corporation tax on profits for the current period
650,369
101,758
Adjustments in respect of prior periods
(45)
Total current tax
650,369
101,713
SSP HEALTH HOLDING LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
8
Taxation
2025
2024
£
£
(Continued)
- 23 -
Deferred tax
Origination and reversal of timing differences
(14,476)
21,217
Total tax charge
635,893
122,930
The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:
2025
2024
£
£
Profit before taxation
2,605,389
628,455
Expected tax charge based on the standard rate of corporation tax in the UK of 25.00% (2024: 25.00%)
651,347
157,114
Tax effect of expenses that are not deductible in determining taxable profit
3,425
18,559
Tax effect of income not taxable in determining taxable profit
(18,559)
Tax effect of utilisation of tax losses not previously recognised
(56,025)
Effect of change in corporation tax rate
-
(11)
Permanent capital allowances in excess of depreciation
(55)
3,336
Under/(over) provided in prior years
(43)
Tax at marginal rate
(265)
Taxation charge
635,893
122,930
The standard rate of tax applied to corporation taxation and deferred taxation balances is 25% (2024 - 25%).
9
Dividends
2025
2024
Recognised as distributions to equity holders:
£
£
Final paid
3,250,000
5,288,437
SSP HEALTH HOLDING LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
- 24 -
10
Intangible fixed assets
Group
Software development costs
£
Cost
At 31 March 2024 and 30 March 2025
134,768
Amortisation and impairment
At 31 March 2024
26,954
Amortisation charged for the year
13,477
At 30 March 2025
40,431
Carrying amount
At 30 March 2025
94,337
At 30 March 2024
107,814
The company had no intangible fixed assets at 30 March 2025 or 30 March 2024.
11
Tangible fixed assets
Group
Leasehold land and buildings
Plant and equipment
Fixtures and fittings
Total
£
£
£
£
Cost
At 31 March 2024
45,674
199,798
129,165
374,637
Additions
243,181
-
-
243,181
Disposals
-
(31,974)
-
(31,974)
At 30 March 2025
288,855
167,824
129,165
585,844
Depreciation and impairment
At 31 March 2024
-
81,696
39,350
121,046
Depreciation charged in the year
-
40,948
18,697
59,645
Eliminated in respect of disposals
-
(31,974)
-
(31,974)
At 30 March 2025
-
90,670
58,047
148,717
Carrying amount
At 30 March 2025
288,855
77,154
71,118
437,127
At 30 March 2024
45,674
118,102
89,815
253,591
The company had no tangible fixed assets at 30 March 2025 or 30 March 2024.
SSP HEALTH HOLDING LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
- 25 -
12
Investment property
Group
Company
2025
2025
£
£
Fair value
At 31 March 2024 and 30 March 2025
1,354,341
-
Additions
2,272,757
-
At 30 March 2025
3,627,098
-
Investment property comprises leased commercial buildings. The properties were acquired by the company during the year and as such the director is satisfied that the value above represents the fair value of the investment properties at the balance sheet date.
13
Fixed asset investments
Group
Company
2025
2024
2025
2024
Notes
£
£
£
£
Investments in subsidiaries
14
-
-
201
101
Unlisted investments
74,237
-
74,237
74,237
-
74,438
101
Movements in fixed asset investments
Group
Investments
£
Cost or valuation
At 31 March 2024
-
Impairment
74,237
At 30 March 2025
74,237
Carrying amount
At 30 March 2025
74,237
At 30 March 2024
-
SSP HEALTH HOLDING LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
13
Fixed asset investments
(Continued)
- 26 -
Movements in fixed asset investments
Company
Shares in subsidiaries
Other investments
Total
£
£
£
Cost or valuation
At 31 March 2024
101
-
101
Additions
100
-
100
Impairment
-
74,237
74,237
At 30 March 2025
201
74,237
74,438
Carrying amount
At 30 March 2025
201
74,237
74,438
At 30 March 2024
101
-
101
14
Subsidiaries
Details of the company's subsidiaries at 30 March 2025 are as follows:
Name of undertaking
Registered office
Class of
% Held
shares held
Direct
SSP Health Medical Services Limited
UK
Ordinary
100.00
SSP Health Primary Care Limited
UK
Ordinary
100.00
SSP Health Properties Ltd
UK
Ordinary
100.00
15
Financial instruments
Group
Company
2025
2024
2025
2024
£
£
£
£
Carrying amount of financial assets
Debt instruments measured at amortised cost
2,115,010
2,930,162
n/a
n/a
Carrying amount of financial liabilities
Measured at amortised cost
6,791,219
3,500,159
n/a
n/a
16
Stocks
Group
Company
2025
2024
2025
2024
£
£
£
£
Finished goods and goods for resale
58,070
58,070
SSP HEALTH HOLDING LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
- 27 -
17
Debtors
Group
Company
2025
2024
2025
2024
Amounts falling due within one year:
£
£
£
£
Trade debtors
405,030
370,676
1
Amounts owed by group undertakings
-
-
3,869,348
-
Other debtors
1,379,282
1,919,865
1,374,775
1,421,768
Prepayments and accrued income
470,480
833,553
2,254,792
3,124,094
5,244,123
1,421,769
18
Creditors: amounts falling due within one year
Group
Company
2025
2024
2025
2024
Notes
£
£
£
£
Other borrowings
19
1,840,000
-
1,840,000
Trade creditors
110,579
172,395
15
Amounts owed to group undertakings
-
-
5,462,509
176,653
Corporation tax payable
433,633
15,389
9,091
13,743
Other taxation and social security
130,918
111,839
-
-
Other creditors
3,118,335
2,237,165
5,030
255,614
Accruals and deferred income
1,722,305
1,090,599
7,355,770
3,627,387
7,316,645
446,010
The group has banking facilities with Santander UK PLC. The facilities include fixed charges & floating charges over all the property or undertaking of the company, the charges also contained a negative pledge.
19
Loans and overdrafts
Group
Company
2025
2024
2025
2024
£
£
£
£
Other loans
1,840,000
1,840,000
Payable within one year
1,840,000
1,840,000
Other borrowings is a loan from a related party. This loan is unsecured, interest free and repayable on demand.
SSP HEALTH HOLDING LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
- 28 -
20
Deferred taxation
Deferred tax assets and liabilities are offset where the group or company has a legally enforceable right to do so. The following is the analysis of the deferred tax balances (after offset) for financial reporting purposes:
Liabilities
Liabilities
2025
2024
Group
£
£
Accelerated capital allowances
30,876
45,352
The company has no deferred tax assets or liabilities.
Group
Company
2025
2025
Movements in the year:
£
£
Liability at 31 March 2024
45,352
-
Credit to profit or loss
(14,476)
-
Liability at 30 March 2025
30,876
-
21
Retirement benefit schemes
2025
2024
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
248,352
266,824
A defined contribution pension scheme is operated for all qualifying employees. The assets of the scheme are held separately from those of the group in an independently administered fund.
22
Share capital
Group and company
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
100
100
100
100
SSP HEALTH HOLDING LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
- 29 -
23
Profit and loss reserves
Group
Company
2025
2024
2025
2024
as restated
as restated
£
£
£
£
At the beginning of the year
8,747,827
8,829,904
5,677,179
6,297,708
Prior year adjustment
(4,700,835)
-
(4,700,835)
-
As restated
4,046,992
8,829,904
976,344
6,297,708
Profit/(loss) for the year
1,969,496
505,525
2,286,810
(32,927)
Dividends
(3,250,000)
(5,288,437)
(3,250,000)
(5,288,437)
At the end of the year
2,766,488
4,046,992
13,154
976,344
24
Related party transactions
Remuneration of key management personnel
2025
2024
£
£
Aggregate compensation
659,887
537,166
Transactions with related parties
The following amounts were outstanding at the reporting end date:
Amounts due to related parties
2025
2024
£
£
Group
Entities under common control
3,065,588
1,879,675
Other related parties
1,840,000
-
Company
Other related parties
1,840,000
-
The amounts owed to/from entities under common control are unsecured, interest free and repayable on demand.
The amount owed from other related parties, is unsecured, has no set repayment date and attracts no interest charge during the year.
SSP HEALTH HOLDING LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
24
Related party transactions
(Continued)
- 30 -
The following amounts were outstanding at the reporting end date:
Amounts due from related parties
2025
2024
Balance
Balance
£
£
Group
Other related parties
1,441,643
1,421,768
Company
Other related parties
1,441,643
1,421,768
The amounts owed to/from entities under common control are unsecured, interest free and repayable on demand.
Other information
Entities under common control and other related parties are entities with common directorship and shareholdings.
Advantage has been taken of FRS102, Section 33.1A available for transactions with wholly owned subsidiaries and has chosen not to disclose related party transactions within the group.
25
Controlling party
By virtue of ownership of the entire issued share capital of the company, Dr S Pitalia is the ultimate controlling party.
26
Cash generated from group operations
2025
2024
£
£
Profit after taxation
1,969,496
505,525
Adjustments for:
Taxation charged
635,893
122,930
Finance costs
414
Investment income
(108,379)
(82,513)
Amortisation and impairment of intangible assets
13,477
13,477
Depreciation and impairment of tangible fixed assets
59,645
43,114
Impairment of investment
(74,237)
411,839
Movements in working capital:
Increase in stocks
-
(25,011)
Decrease in debtors
822,309
978,872
Increase in creditors
841,194
511,947
Cash generated from operations
4,159,812
2,480,180
SSP HEALTH HOLDING LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
- 31 -
27
Analysis of changes in net funds - group
31 March 2024
Cash flows
30 March 2025
£
£
£
Cash at bank and in hand
2,821,921
785,652
3,607,573
Borrowings excluding overdrafts
-
(1,840,000)
(1,840,000)
2,821,921
(1,054,348)
1,767,573
28
Prior period adjustment
Reconciliation of changes in equity - group
31 March
30 March
2023
2024
£
£
Adjustments to prior year
Investment disposal and reversal of impairment
1
-
(4,700,835)
Equity as previously reported
8,830,004
8,747,927
Equity as adjusted
8,830,004
4,047,092
Analysis of the effect upon equity
Profit and loss reserves
-
(4,700,835)
Reconciliation of changes in profit for the previous financial period
2024
£
Adjustments to prior year
Investment disposal and reversal of impairment
1
337,602
Profit as previously reported
167,923
Profit as adjusted
505,525
Reconciliation of changes in equity - company
31 March
30 March
2023
2024
Notes
£
£
Adjustments to prior year
Investment disposal
1
-
(4,700,835)
Equity as previously reported
6,297,808
5,677,279
Equity as adjusted
6,297,808
976,444
Analysis of the effect upon equity
Profit and loss reserves
-
(4,700,835)
SSP HEALTH HOLDING LTD
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 MARCH 2025
28
Prior period adjustment
(Continued)
- 32 -
Reconciliation of changes in loss for the previous financial period
2024
Notes
£
Adjustments to prior year
Investment disposal
1
337,602
Loss as previously reported
(370,529)
Loss as adjusted
(32,927)
Notes to reconciliation
Investment disposal
Management have identified that in the prior year investments totalling £5,038,437 were transferred by the company to its director.
This transfer has been amended in these financial statements and has the impact of reducing the impairment during the prior year by £337,602 and thus reducing the loss by the same amount and decreasing the retained earnings of the company and group by £4,700,835.
2025-03-302024-03-31falsefalseCCH SoftwareCCH Accounts Production 2025.300Dr S Pitaliafalse08292124bus:Consolidated2024-03-312025-03-30082921242024-03-312025-03-30082921242025-03-3008292124bus:Director12024-03-312025-03-3008292124bus:RegisteredOffice2024-03-312025-03-3008292124bus:Consolidated2025-03-30082921242024-03-3008292124core:CurrentFinancialInstrumentscore:WithinOneYear2025-03-3008292124core:CurrentFinancialInstrumentscore:WithinOneYear2024-03-3008292124core:CurrentFinancialInstruments2025-03-3008292124core:CurrentFinancialInstruments2024-03-3008292124core:ShareCapital2025-03-3008292124core:ShareCapital2024-03-3008292124core:RetainedEarningsAccumulatedLosses2025-03-3008292124core:RetainedEarningsAccumulatedLosses2024-03-3008292124core:ShareCapital2023-03-3008292124core:RetainedEarningsAccumulatedLosses2023-03-30082921242023-03-3008292124core:RetainedEarningsAccumulatedLossesbus:Consolidated2025-03-3008292124dpl:Item12023-03-312024-03-30082921242023-03-312024-03-3008292124dpl:Item12024-03-312025-03-3008292124core:IntangibleAssetsOtherThanGoodwill2024-03-312025-03-3008292124core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2024-03-312025-03-3008292124core:LandBuildingscore:LongLeaseholdAssets2024-03-312025-03-3008292124core:PlantMachinery2024-03-312025-03-3008292124core:FurnitureFittings2024-03-312025-03-300829212412024-03-312025-03-3008292124bus:Consolidated2023-03-312024-03-3008292124core:UKTaxbus:Consolidated2024-03-312025-03-3008292124core:UKTaxbus:Consolidated2023-03-312024-03-3008292124bus:Consolidated12024-03-312025-03-3008292124bus:Consolidated12023-03-312024-03-3008292124bus:Consolidated22024-03-312025-03-3008292124bus:Consolidated22023-03-312024-03-3008292124core:UnlistedNon-exchangeTraded2025-03-3008292124core:UnlistedNon-exchangeTraded2024-03-3008292124core:Subsidiary12024-03-312025-03-3008292124core:Subsidiary22024-03-312025-03-3008292124core:Subsidiary32024-03-312025-03-3008292124core:Subsidiary112024-03-312025-03-3008292124core:Subsidiary222024-03-312025-03-3008292124core:Subsidiary332024-03-312025-03-3008292124core:CurrentFinancialInstrumentsbus:Consolidated2025-03-3008292124core:CurrentFinancialInstrumentsbus:Consolidated2024-03-3008292124core:CurrentFinancialInstrumentsbus:Consolidated12025-03-3008292124core:CurrentFinancialInstrumentsbus:Consolidated12024-03-3008292124core:CurrentFinancialInstruments22025-03-3008292124core:CurrentFinancialInstruments32025-03-3008292124bus:Consolidated2024-03-3008292124core:WithinOneYearbus:Consolidated2025-03-3008292124core:WithinOneYearbus:Consolidated2024-03-3008292124bus:PrivateLimitedCompanyLtd2024-03-312025-03-3008292124bus:FRS1022024-03-312025-03-3008292124bus:Audited2024-03-312025-03-3008292124bus:ConsolidatedGroupCompanyAccounts2024-03-312025-03-3008292124bus:FullAccounts2024-03-312025-03-30xbrli:purexbrli:sharesiso4217:GBP